Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: A Hellenic Cooperative Oncology Group (HeCOG) phase II study

Medical Oncology

Volumn 24, Issue 3, 2007, Pages 301-307

  Makatsoris, Thomas ^a   Papakostas, Pavlos ^b   Kalofonos, Haralabos P ^a   Xanthakis, Ioannis ^c   Tsavdaridis, Dimitrios ^d   Aravantinos, Gerasimos ^e   Gogas, Helen ^f   Klouvas, George ^g   Kosmidis, Paris ^h   Pectasides, Dimitrios ⁱ   Fountzilas, George ^c  

^a UNIVERSITY OF PATRAS   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d IKA Hospital   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

^g HENRY DUNANT HOSPITAL   (Greece)

^h HYGEIA HOSPITAL   (Greece)

ⁱ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Advanced gastric cancer; Carboplatin; Docetaxel; Epirubicin

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; GASTRITIS; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 36248950187     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0004-1     Document Type: Article

References (25)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.
2. Akoh AJ, McIntyre IMC. Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293-9.
3. Wagner AD, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
4. Cullinan SA, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985;253:2061-7.
5. Wils J. The treatment of advanced gastric cancer. Semin in Oncol 1996;23:397-406.
6. Webb A, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
7. Kelsen D, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
8. Cascinu S, et al. Intensive weekly chemotherapy for advanced gastric cancer using 5-fluorouracil, cisplatin, epi-doxorubicin, 6Sleucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997;15:3313-9.
9. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15:1585-95.
10. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-8.
11. Hainsworth JD, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol 2001;19:3500-5.
12. Miller AB, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
13. Calvert AH, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;17:1748-56.
14. Graziano F, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000;11:1263-6.
15. Chun JH, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005;28:188-94.
16. Orditura M, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Ann Oncol 2006; 17:1529-32.
17. Park SR, et al. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 2006;94:1402-6.
18. Beer M, et al. A phase II study of carboplatin in advanced or metastatic stomach cancer. Eur J Cancer Clin Oncol 1987;23:1565-7.
19. Preusser P, et al. Phase II study of carboplatin in untreated inoperable advanced stomach cancer. Eur J Cancer 1990;26:1108-9.
20. Elsaid A, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin, and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. J Clin Oncol 2005;23:16s, (abstr 4014).
21. Cocconi G, et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994;12:2687-93.
22. Van Cutsem E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
23. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10:49-58.
24. Cunningham D, et al. Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL-2 trial. J Clin Oncol 2006;24:18s (abstr LBA4017).
25. Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. J Clin Oncol 2005;23:16s (abstr 4003).